Vladimir Stojšić
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vladimir Stojšić has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Bojan Zaric
Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia
8 shared publications - Tomi Kovacevic
Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia
8 shared publications - Daliborka Bursac
Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia
5 shared publications - Jelena Djekic Malbasa
Faculty of Medicine, University of Novi Sad, 21137 Novi Sad, Serbia
4 shared publications - Darijo Bokan
Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia
3 shared publications - Goran Stojanovic
Institute for Pulmonary Diseases of Vojvodina, 21204 Sremska Kamenica, Serbia
3 shared publications
Latest Publications
- Open Access
- 27 February 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (5) , 709
Independent Predictors Associated with Patient Refusal of Invasive Diagnostic Procedures After Positive LDCT Lung Cancer Screening
Background: Low-dose computed tomography (LDCT) screening reduces lung cancer mortality; however, the effectiveness of screening programs depends not only on detection, but also on completion of downstream diagnostic pathways following a positive screening result. Refusal of recommended invasive diagnostic procedures represents a critical but understudied form of post-screening attrition. Methods: This retrospective observational study was conducted within an organized multicenter LDCT lung cancer screening program in Vojvodina, Serbia. Consecutive participants screened between September 2020 and October 2025 were included. Positive screening was defined as Lung-RADS 4A, 4B, or 4X. Refusal was defined as the absence of any invasive diagnostic procedure within six months following multidisciplinary team recommendation. Demographic, clinical, smoking-related, and perceptual factors were analyzed. Time to invasive diagnostic procedures was assessed for bronchoscopy and surgical treatment. Multivariable logistic regression was used to identify factors independently associated with refusal. Results: Among 10,261 screened individuals, 479 (4.7%) had positive LDCT findings. Of these, 60 participants (12.5%) refused invasive diagnostic evaluation. In multivariable analysis, multimorbidity (OR 3.45, 95% CI 1.61–7.38), previous malignancy (OR 2.92, 95% CI 1.16–7.35), higher cumulative smoking exposure (OR 1.02 per pack-year, 95% CI 1.00–1.03), and screening center (Subotica vs. Novi Sad: OR 2.40, 95% CI 1.21–4.78) were independently associated with refusal of invasive diagnostic procedures. Greater concern about personal lung cancer risk was associated with a lower likelihood of refusal (OR 0.54, 95% CI 0.29–0.99). Time to bronchoscopy differed significantly across screening centers and screening years, whereas time to surgical treatment was comparable across centers and years. Conclusions: Refusal of invasive diagnostic procedures following positive LDCT screening represents a meaningful implementation challenge influenced by both patient vulnerability and system-level factors. Addressing modifiable barriers through improved risk communication and optimization of post-screening diagnostic pathways may enhance diagnostic continuity and strengthen the real-world effectiveness of lung cancer screening programs.
- 27 February 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (5) , 709
Open AccessIndependent Predictors Associated with Patient Refusal of Invasive Diagnostic Procedures After Positive LDCT Lung Cancer Screening
Background: Low-dose computed tomography (LDCT) screening reduces lung cancer mortality; however, the effectiveness of screening programs depends not only on detection, but also on completion of downstream diagnostic pathways following a positive screening result. Refusal of recommended invasive diagnostic procedures represents a critical but understudied form of post-screening attrition. Methods: This retrospective observational study was conducted within an organized multicenter LDCT lung cancer screening program in Vojvodina, Serbia. Consecutive participants screened between September 2020 and October 2025 were included. Positive screening was defined as Lung-RADS 4A, 4B, or 4X. Refusal was defined as the absence of any invasive diagnostic procedure within six months following multidisciplinary team recommendation. Demographic, clinical, smoking-related, and perceptual factors were analyzed. Time to invasive diagnostic procedures was assessed for bronchoscopy and surgical treatment. Multivariable logistic regression was used to identify factors independently associated with refusal. Results: Among 10,261 screened individuals, 479 (4.7%) had positive LDCT findings. Of these, 60 participants (12.5%) refused invasive diagnostic evaluation. In multivariable analysis, multimorbidity (OR 3.45, 95% CI 1.61–7.38), previous malignancy (OR 2.92, 95% CI 1.16–7.35), higher cumulative smoking exposure (OR 1.02 per pack-year, 95% CI 1.00–1.03), and screening center (Subotica vs. Novi Sad: OR 2.40, 95% CI 1.21–4.78) were independently associated with refusal of invasive diagnostic procedures. Greater concern about personal lung cancer risk was associated with a lower likelihood of refusal (OR 0.54, 95% CI 0.29–0.99). Time to bronchoscopy differed significantly across screening centers and screening years, whereas time to surgical treatment was comparable across centers and years. Conclusions: Refusal of invasive diagnostic procedures following positive LDCT screening represents a meaningful implementation challenge influenced by both patient vulnerability and system-level factors. Addressing modifiable barriers through improved risk communication and optimization of post-screening diagnostic pathways may enhance diagnostic continuity and strengthen the real-world effectiveness of lung cancer screening programs.
- Open Access
- 13 February 2026
- Published by MDPI AG in Preprints.org
Independent Predictors Associated With Refusal of Invasive Diagnostic Procedures after Positive LDCT Lung Cancer Screening
Background: Low-dose computed tomography (LDCT) screening reduces lung cancer mortality; however, the effectiveness of screening programs depends not only on detection, but also on completion of downstream diagnostic pathways following a positive screening result. Refusal of recommended invasive diagnostic procedures represents a critical but understudied form of post-screening attrition. Methods: This retrospective observational study was conducted within an organized multicentre LDCT lung cancer screening program in Vojvodina, Serbia. Consecutive participants screened between October 2020 and October 2025 were included. Positive screening was defined as Lung-RADS 4A, 4B, or 4X. Refusal was defined as the absence of any invasive diagnostic procedure within six months following multidisciplinary team recommendation. Demographic, clinical, smoking-related, and perceptual factors were analyzed. Time to invasive diagnostic procedures was assessed for bronchoscopy and surgical treatment. Multivariable logistic regression was used to identify factors independently associated with refusal. Results: Among 10,261 screened individuals, 479 (4.7%) had positive LDCT findings. Of these, 60 participants (12.5%) refused invasive diagnostic evaluation. Refusal was significantly associated with higher cumulative smoking exposure, multimorbidity, previous malignancy, screening site, and lower perceived lung cancer risk. In multivariable analysis, multimorbidity (OR 3.49, 95% CI 1.62–7.51), previous malignancy (OR 2.81, 95% CI 1.04–7.58), and cumulative smoking exposure (OR 0.98 per pack-year, 95% CI 0.97–0.995) remained independently associated with refusal. Time to bronchoscopy differed significantly across screening centers and screening years, whereas time to surgical treatment was comparable across centers and years. Conclusions: Refusal of invasive diagnostic procedures following positive LDCT screening represents a meaningful implementation challenge influenced by both patient vulnerability and system-level factors. Addressing modifiable barriers through improved risk communication and optimization of post-screening diagnostic pathways may enhance diagnostic continuity and strengthen the real-world effectiveness of lung cancer screening programs.
- 13 February 2026
- Published by MDPI AG in Preprints.org
Open AccessIndependent Predictors Associated With Refusal of Invasive Diagnostic Procedures after Positive LDCT Lung Cancer Screening
Background: Low-dose computed tomography (LDCT) screening reduces lung cancer mortality; however, the effectiveness of screening programs depends not only on detection, but also on completion of downstream diagnostic pathways following a positive screening result. Refusal of recommended invasive diagnostic procedures represents a critical but understudied form of post-screening attrition. Methods: This retrospective observational study was conducted within an organized multicentre LDCT lung cancer screening program in Vojvodina, Serbia. Consecutive participants screened between October 2020 and October 2025 were included. Positive screening was defined as Lung-RADS 4A, 4B, or 4X. Refusal was defined as the absence of any invasive diagnostic procedure within six months following multidisciplinary team recommendation. Demographic, clinical, smoking-related, and perceptual factors were analyzed. Time to invasive diagnostic procedures was assessed for bronchoscopy and surgical treatment. Multivariable logistic regression was used to identify factors independently associated with refusal. Results: Among 10,261 screened individuals, 479 (4.7%) had positive LDCT findings. Of these, 60 participants (12.5%) refused invasive diagnostic evaluation. Refusal was significantly associated with higher cumulative smoking exposure, multimorbidity, previous malignancy, screening site, and lower perceived lung cancer risk. In multivariable analysis, multimorbidity (OR 3.49, 95% CI 1.62–7.51), previous malignancy (OR 2.81, 95% CI 1.04–7.58), and cumulative smoking exposure (OR 0.98 per pack-year, 95% CI 0.97–0.995) remained independently associated with refusal. Time to bronchoscopy differed significantly across screening centers and screening years, whereas time to surgical treatment was comparable across centers and years. Conclusions: Refusal of invasive diagnostic procedures following positive LDCT screening represents a meaningful implementation challenge influenced by both patient vulnerability and system-level factors. Addressing modifiable barriers through improved risk communication and optimization of post-screening diagnostic pathways may enhance diagnostic continuity and strengthen the real-world effectiveness of lung cancer screening programs.
- Open Access
- 29 October 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (21) , 2734
Nodule Characteristics, Clinical Risk Factors, and Radiologist Experience as Predictors of Positive Baseline LDCT Screening Results
Background/Objectives: Early detection of lung cancer through low-dose computed tomography (LDCT) significantly improves patient outcomes. Identifying predictors of positive baseline LDCT findings can optimize screening programs and cost-effectiveness, particularly in regional settings. Methods: We conducted a retrospective analysis of baseline LDCT screenings performed in 2024 at three sites in Vojvodina, Serbia. Eligible participants were adults aged 50–74 years with a significant smoking history. Lung nodules were evaluated using the Lung-RADS system. Sociodemographic, clinical, and nodule-related variables, as well as radiologist experience (>10 vs. <10 years), were assessed. Multivariable logistic regression identified independent predictors of positive LDCT outcomes (Lung-RADS 3, 4A, 4B, 4X). Results: Overall, 17.6% (613/3479) of participants had positive baseline LDCT findings. Multivariable analysis showed that nodule type (semi-solid: OR = 4.01, 95% CI: 1.46–11.01; solid: OR = 8.86, 95% CI: 4.53–17.32), nodule morphology (smooth: OR = 0.42, 95% CI: 0.22–0.81; perifissural: OR = 0.16, 95% CI: 0.08–0.33; endobronchial: OR = 47.99, 95% CI: 12.35–186.58), nodule diameter (OR = 1.83 per mm, 95% CI: 1.71–1.96), presence of COPD (OR = 1.95, 95% CI: 1.23–3.08), age (OR = 1.02 per year, 95% CI: 1.00–1.04), and radiologist <10 years working experience (OR = 1.47, 95% CI: 1.23–3.08) were independent predictors of positivity. Conclusions: Baseline LDCT positivity is influenced by nodule characteristics, patient sociodemographic and clinical factors, and radiologist experience. These findings can inform targeted screening strategies in high-risk populations.
- 29 October 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (21) , 2734
Open AccessNodule Characteristics, Clinical Risk Factors, and Radiologist Experience as Predictors of Positive Baseline LDCT Screening Results
Background/Objectives: Early detection of lung cancer through low-dose computed tomography (LDCT) significantly improves patient outcomes. Identifying predictors of positive baseline LDCT findings can optimize screening programs and cost-effectiveness, particularly in regional settings. Methods: We conducted a retrospective analysis of baseline LDCT screenings performed in 2024 at three sites in Vojvodina, Serbia. Eligible participants were adults aged 50–74 years with a significant smoking history. Lung nodules were evaluated using the Lung-RADS system. Sociodemographic, clinical, and nodule-related variables, as well as radiologist experience (>10 vs. <10 years), were assessed. Multivariable logistic regression identified independent predictors of positive LDCT outcomes (Lung-RADS 3, 4A, 4B, 4X). Results: Overall, 17.6% (613/3479) of participants had positive baseline LDCT findings. Multivariable analysis showed that nodule type (semi-solid: OR = 4.01, 95% CI: 1.46–11.01; solid: OR = 8.86, 95% CI: 4.53–17.32), nodule morphology (smooth: OR = 0.42, 95% CI: 0.22–0.81; perifissural: OR = 0.16, 95% CI: 0.08–0.33; endobronchial: OR = 47.99, 95% CI: 12.35–186.58), nodule diameter (OR = 1.83 per mm, 95% CI: 1.71–1.96), presence of COPD (OR = 1.95, 95% CI: 1.23–3.08), age (OR = 1.02 per year, 95% CI: 1.00–1.04), and radiologist <10 years working experience (OR = 1.47, 95% CI: 1.23–3.08) were independent predictors of positivity. Conclusions: Baseline LDCT positivity is influenced by nodule characteristics, patient sociodemographic and clinical factors, and radiologist experience. These findings can inform targeted screening strategies in high-risk populations.
- Open Access
- 23 October 2025
- Published by Scientific Scholar in Cytojournal
- Vol. 22, 85
A brief overview of imprint cytology in thoracic cytopathology
A brief overview of imprint cytology in thoracic cytopathology
- 23 October 2025
- Published by Scientific Scholar in Cytojournal
- Vol. 22, 85
Open AccessA brief overview of imprint cytology in thoracic cytopathology
A brief overview of imprint cytology in thoracic cytopathology
- Open Access
- 16 June 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (6) , 3350-3360
Attitudes toward Death among Health Care Professionals in the Balkan Region
Background and Objectives: Death is an unavoidable experience in any person’s life and affects not only the dying person but also their caregivers. The dying process has been displaced from homes to health care facilities in the majority of cases. Facing death and dying has become an everyday life of health care professionals (HCP), especially in palliative care (PC) settings. This study aimed to investigate the death attitudes among HCPs in Serbia. Materials and Methods: The Serbian version of the Death Attitude Profile-Revised (DAP-RSp) was used as a measurement instrument. Results: The average age of the 180 included participants was 42.2 ± 9.9 years; the majority were females (70.0%), with more than 10 years of working experience (73.0%), physicians (70.0%) and those working in a non-oncological (non-ONC) field (57.78%). The mean total score of DAP-RSp was 124.80 ± 22.44. The highest mean score was observed in the neutral acceptance dimension (NA) (5.82 ± 0.90) and lowest in the Escape acceptance (EA) (2.57 ± 1.21). Higher negative death attitudes were reported among nurses compared to physicians (p = 0.002). Statistically significant differences were observed in the fear of death (FD) and death avoidance (DA) domains, favoring PC specialists and oncologists (p = 0.004; p = 0.015). Physicians working in Oncology (ONC) showed lower FD values (p = 0.001) compared to non-ONC departments. Conclusions: Attitudes toward death among HCPs are of great importance for the well-being of both HCPs and patients. Negative attitudes can lead to deficient care. The fear of death is highly represented among Serbian HCPs working in non-ONC fields, including both nurses and physicians. This study emphasizes the need for further research to comprehensively explore and understand HCPs’ attitudes toward death. This research highlights the need for the development of an educational curriculum across all levels of medical education, aimed at overcoming the fear of death and enhancing coping strategies, which will improve the care for patients diagnosed with terminal illnesses.
- 16 June 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (6) , 3350-3360
Open AccessAttitudes toward Death among Health Care Professionals in the Balkan Region
Background and Objectives: Death is an unavoidable experience in any person’s life and affects not only the dying person but also their caregivers. The dying process has been displaced from homes to health care facilities in the majority of cases. Facing death and dying has become an everyday life of health care professionals (HCP), especially in palliative care (PC) settings. This study aimed to investigate the death attitudes among HCPs in Serbia. Materials and Methods: The Serbian version of the Death Attitude Profile-Revised (DAP-RSp) was used as a measurement instrument. Results: The average age of the 180 included participants was 42.2 ± 9.9 years; the majority were females (70.0%), with more than 10 years of working experience (73.0%), physicians (70.0%) and those working in a non-oncological (non-ONC) field (57.78%). The mean total score of DAP-RSp was 124.80 ± 22.44. The highest mean score was observed in the neutral acceptance dimension (NA) (5.82 ± 0.90) and lowest in the Escape acceptance (EA) (2.57 ± 1.21). Higher negative death attitudes were reported among nurses compared to physicians (p = 0.002). Statistically significant differences were observed in the fear of death (FD) and death avoidance (DA) domains, favoring PC specialists and oncologists (p = 0.004; p = 0.015). Physicians working in Oncology (ONC) showed lower FD values (p = 0.001) compared to non-ONC departments. Conclusions: Attitudes toward death among HCPs are of great importance for the well-being of both HCPs and patients. Negative attitudes can lead to deficient care. The fear of death is highly represented among Serbian HCPs working in non-ONC fields, including both nurses and physicians. This study emphasizes the need for further research to comprehensively explore and understand HCPs’ attitudes toward death. This research highlights the need for the development of an educational curriculum across all levels of medical education, aimed at overcoming the fear of death and enhancing coping strategies, which will improve the care for patients diagnosed with terminal illnesses.
- Open Access
- 1 January 2024
- Published by Centre for Evaluation in Education and Science (CEON/CEES)
- No. Oral prese,p. 92
Stages and types of lung cancers in the pilot lung cancer screening program in Vojodina, Serbia
Background: Lung cancer (LC) screening with LDCT reduces LC mortality by 20% due to detection in the early stage of the disease. The aim was to analyze LC stages, histological types, and demographic characteristics of LC patients in the pilot LC screening program in Vojvodina from October 2020 to July 2024. Objectives and Methods: Persons aged 50-74 years, with a smoking history of 30 pack-years or more or 20 pack-years with additional risks (COPD, prior pneumonia, other malignancy, LC hereditary history) underwent LDCT evaluation. Radiological assessment and further evaluation were done per Lung RADS score. Results: During the observed period, a total of 9,006 LDCT scans were performed on 5,483 screen participants. The majority were females (58.2%). Prevalence of Lung RADS scores 0, 1, 2, 3, 4A, 4B and 4X were respectively 1.0%, 41.0%, 40.5%, 7.8%, 6.5%, 1.1% and 2.0%. The total number of patients with malignancy was 108, and the LC detection rate was 1.8%. From a total number of LC, 54.4% were detected among males. The average age of LC patients was 66 years (65.79±8.97), with no observed differences by gender (p=0.218). Percentage of LC by stage I, II, IIIA, IIIB and IV were respectively 48.5%, 12.6%, 8.7%, 10.7%, and 19.4%. From 2021 to 2024 percentage of LC stage I by years was 31.8%, 48.0%, 54.5% and 58.3%, respectively. Among LC types, 86.3% were NSCLC (adenocarcinoma 52.4%, squamous cell carcinoma 25.2%, NOS 8.7%), 9.7% were SCLC, and 3.9% other types. Conclusion: Lung RADS score positive results were found in 9.6% of screening participants. 61.7% of LCs detected in screening were in the I and II stages.
- 1 January 2024
- Published by Centre for Evaluation in Education and Science (CEON/CEES)
- No. Oral prese,p. 92
Open AccessStages and types of lung cancers in the pilot lung cancer screening program in Vojodina, Serbia
Background: Lung cancer (LC) screening with LDCT reduces LC mortality by 20% due to detection in the early stage of the disease. The aim was to analyze LC stages, histological types, and demographic characteristics of LC patients in the pilot LC screening program in Vojvodina from October 2020 to July 2024. Objectives and Methods: Persons aged 50-74 years, with a smoking history of 30 pack-years or more or 20 pack-years with additional risks (COPD, prior pneumonia, other malignancy, LC hereditary history) underwent LDCT evaluation. Radiological assessment and further evaluation were done per Lung RADS score. Results: During the observed period, a total of 9,006 LDCT scans were performed on 5,483 screen participants. The majority were females (58.2%). Prevalence of Lung RADS scores 0, 1, 2, 3, 4A, 4B and 4X were respectively 1.0%, 41.0%, 40.5%, 7.8%, 6.5%, 1.1% and 2.0%. The total number of patients with malignancy was 108, and the LC detection rate was 1.8%. From a total number of LC, 54.4% were detected among males. The average age of LC patients was 66 years (65.79±8.97), with no observed differences by gender (p=0.218). Percentage of LC by stage I, II, IIIA, IIIB and IV were respectively 48.5%, 12.6%, 8.7%, 10.7%, and 19.4%. From 2021 to 2024 percentage of LC stage I by years was 31.8%, 48.0%, 54.5% and 58.3%, respectively. Among LC types, 86.3% were NSCLC (adenocarcinoma 52.4%, squamous cell carcinoma 25.2%, NOS 8.7%), 9.7% were SCLC, and 3.9% other types. Conclusion: Lung RADS score positive results were found in 9.6% of screening participants. 61.7% of LCs detected in screening were in the I and II stages.
- Open Access
- 1 January 2022
- Published by National Library of Serbia in Vojnosanitetski Pregled
- Vol. 79 (5) , 481-487
Mortality of COVID-19 pneumonia during anticancer treatment in lung cancer patients
Background/Aim: The COVID-19 pandemic has multiple impacts on the management of cancer patients. Treatment of malignancies, including chemotherapy, targeted therapy, immunotherapy and radiotherapy, can suppress the immune system and lead to the development of severe complications of COVID-19 infection. The aim of this study was to determine the mortality of lung cancer (LC) patients, in whom the COVID-19 infection was confirmed during active antitumor treatment. Methods: This retrospective study was conducted at the Institute for Pulmonary Diseases of Vojvodina. All patients included in the study underwent active anticancer treatment at the time of diagnosis of COVID-19. SARS-CoV-2 infection was determined with polymerase chain reaction test (PCR). Patient data were collected using the institutional database and observed period was from November 20, 2020 to June 5, 2021. Statistical analysis of the derived patient’s data using the multivariate and univariate testing. Results: Out of total 828 observed COVID-19 hospitalized patients 81 were LC patient on active antitumor treatment. Patients were predominantly male (67.9%), smokers (55.6%), 66.47 years old (range 43-83). Majority of patients (50.6%) were Eastern Cooperative Oncology Group performance status (ECOG PS) 1 and 83.9% had at least one comorbidity. The most common comorbidities were arterial hypertension (66.7%), chronic obstructive pulmonary disease (COPD) (28.4%) and diabetes (21%). Obesity, congestive heart failure and other cardiovascular diseases were present in 11%, 6.2% and 7.4% of patients. The most common was adenocarcinoma (33.3%), followed by squamous (30.9%) and small-cell lung cancer (24.7%). Predominantly 63% of the patients were in stage III of disease and 33.3% were in stage IV. Metastases were most commonly present in the contralateral lung/pleura (14.8%), brain (6.2%), bone (3.7%) and liver (3.7%). Systemic anticancer therapy was applied in 37/81 patients (45.6%), chest radiotherapy in 35/81 (43.2%), concurrent chemoradiotherapy in 1/81 (1.2%) and other types of radiotherapy in 8/81 patients (9.87%). The most common forms of systemic therapy were chemotherapy (35.8%), immunotherapy (7.4%) and targeted therapy (2.4%) patients. Most common chemotherapy was cisplatin-based regiment applied in 34.6% of patients. The mortality from COVID-19 was 19.8%. The statistically significance in relation to the type of treatment was not observed (p = 0.973). Statistical significance was observed between mortality and ECOG PS (p = 0.011). Conclusions: LC patients are dependent on antitumor treatment and at the same time highly susceptible to potential infection. In this study we did not find statistically significant differences in mortality related to the type of antitumor treatment in COVID-19 positive LC patients. Further detailed research on larger scale is needed to be performed in order to explore the effects of SARS-CoV-2 on cancer patients. All possible methods of protection against SARS-CoV-2 virus should be performed in order to minimize the risk of infection in all but especially in immunocompromised cancer patients.
- 1 January 2022
- Published by National Library of Serbia in Vojnosanitetski Pregled
- Vol. 79 (5) , 481-487
Open AccessMortality of COVID-19 pneumonia during anticancer treatment in lung cancer patients
Background/Aim: The COVID-19 pandemic has multiple impacts on the management of cancer patients. Treatment of malignancies, including chemotherapy, targeted therapy, immunotherapy and radiotherapy, can suppress the immune system and lead to the development of severe complications of COVID-19 infection. The aim of this study was to determine the mortality of lung cancer (LC) patients, in whom the COVID-19 infection was confirmed during active antitumor treatment. Methods: This retrospective study was conducted at the Institute for Pulmonary Diseases of Vojvodina. All patients included in the study underwent active anticancer treatment at the time of diagnosis of COVID-19. SARS-CoV-2 infection was determined with polymerase chain reaction test (PCR). Patient data were collected using the institutional database and observed period was from November 20, 2020 to June 5, 2021. Statistical analysis of the derived patient’s data using the multivariate and univariate testing. Results: Out of total 828 observed COVID-19 hospitalized patients 81 were LC patient on active antitumor treatment. Patients were predominantly male (67.9%), smokers (55.6%), 66.47 years old (range 43-83). Majority of patients (50.6%) were Eastern Cooperative Oncology Group performance status (ECOG PS) 1 and 83.9% had at least one comorbidity. The most common comorbidities were arterial hypertension (66.7%), chronic obstructive pulmonary disease (COPD) (28.4%) and diabetes (21%). Obesity, congestive heart failure and other cardiovascular diseases were present in 11%, 6.2% and 7.4% of patients. The most common was adenocarcinoma (33.3%), followed by squamous (30.9%) and small-cell lung cancer (24.7%). Predominantly 63% of the patients were in stage III of disease and 33.3% were in stage IV. Metastases were most commonly present in the contralateral lung/pleura (14.8%), brain (6.2%), bone (3.7%) and liver (3.7%). Systemic anticancer therapy was applied in 37/81 patients (45.6%), chest radiotherapy in 35/81 (43.2%), concurrent chemoradiotherapy in 1/81 (1.2%) and other types of radiotherapy in 8/81 patients (9.87%). The most common forms of systemic therapy were chemotherapy (35.8%), immunotherapy (7.4%) and targeted therapy (2.4%) patients. Most common chemotherapy was cisplatin-based regiment applied in 34.6% of patients. The mortality from COVID-19 was 19.8%. The statistically significance in relation to the type of treatment was not observed (p = 0.973). Statistical significance was observed between mortality and ECOG PS (p = 0.011). Conclusions: LC patients are dependent on antitumor treatment and at the same time highly susceptible to potential infection. In this study we did not find statistically significant differences in mortality related to the type of antitumor treatment in COVID-19 positive LC patients. Further detailed research on larger scale is needed to be performed in order to explore the effects of SARS-CoV-2 on cancer patients. All possible methods of protection against SARS-CoV-2 virus should be performed in order to minimize the risk of infection in all but especially in immunocompromised cancer patients.
- Open Access
- 31 December 2021
- Vol. 47 (4) , 507-515
Long Term Respiratory Follow-Up for COVID-19 Patients a Multicenter Study
Background: The first wave of the COVID-19 pandemic initiated officially in October 2020. Since then several observations have been made regarding the disease and its symptoms. Patients and Methods: We included eighty seven in our observational study. Our main aim was to investigate their long term respiratory follow-up in correlation with their initial radiological and laboratory findings and values. The nose swab PCR test for COVID-19 was used for diagnosis. Patients were monitored at 3 and 6 months after their hospital reception whereas basic parameters of health condition (smoking, PO2, SPO2, WBC, CXR, CRP, intercurrent findings, days of nursing, colchicine administration) in joint with gender and age were recorded. Results: Males seem more susceptible to the viral disease than females in a ratio 1,8:1. The parameters FEV1 and FVC (as % relative changes) were not affected, apart from the DLCO to which CRP (in loge+1 transformation) and SPO2 showed a statistically significant effect. Conclusion: None of these patients were intubated, or admitted to the intensive care unit. The respiratory function is affected by the virus and the effect is reversed within the first three months. Males are more affected and the radiological and laboratory findings are associated with the respiratory functions.
- 31 December 2021
- Vol. 47 (4) , 507-515
Open AccessLong Term Respiratory Follow-Up for COVID-19 Patients a Multicenter Study
Background: The first wave of the COVID-19 pandemic initiated officially in October 2020. Since then several observations have been made regarding the disease and its symptoms. Patients and Methods: We included eighty seven in our observational study. Our main aim was to investigate their long term respiratory follow-up in correlation with their initial radiological and laboratory findings and values. The nose swab PCR test for COVID-19 was used for diagnosis. Patients were monitored at 3 and 6 months after their hospital reception whereas basic parameters of health condition (smoking, PO2, SPO2, WBC, CXR, CRP, intercurrent findings, days of nursing, colchicine administration) in joint with gender and age were recorded. Results: Males seem more susceptible to the viral disease than females in a ratio 1,8:1. The parameters FEV1 and FVC (as % relative changes) were not affected, apart from the DLCO to which CRP (in loge+1 transformation) and SPO2 showed a statistically significant effect. Conclusion: None of these patients were intubated, or admitted to the intensive care unit. The respiratory function is affected by the virus and the effect is reversed within the first three months. Males are more affected and the radiological and laboratory findings are associated with the respiratory functions.
- Open Access
- 10 May 2021
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 14 (2) , 716-724
Personalized Approach to Tissue and Liquid Biopsy after Failure of First-Line EGFR-TKIs: Is There an Issue When Tissue Is Not the Issue? A Case Series
Traditionally, tissue availability from rebiopsy is a prerequisite for adequate sequencing of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in therapy for advanced-stage lung cancer. Tissue biopsy truly is the gold standard for genetic analyses, but in some cases, such as with inadequate localization of the lesion or a patient’s inadequate performance status, comorbidities, or unwillingness to undergo an invasive procedure, liquid biopsy-based ctDNA analysis can be a noninvasive alternative approach. However, in some cases the gold standard might not shine that much. It is known that tumor heterogeneity or an inadequate amount of tissue might significantly interfere with the results of testing. In this paper, we present cases of patients with a negative tissue biopsy but a positive liquid biopsy which identified coexisting T790M mutation. These results enabled adequate sequencing and treatment with third-line EGFR-TKIs. Such possibilities stress the need to individualize testing for driver mutations in cases where it is clinically highly indicated.
- 10 May 2021
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 14 (2) , 716-724
Open AccessPersonalized Approach to Tissue and Liquid Biopsy after Failure of First-Line EGFR-TKIs: Is There an Issue When Tissue Is Not the Issue? A Case Series
Traditionally, tissue availability from rebiopsy is a prerequisite for adequate sequencing of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in therapy for advanced-stage lung cancer. Tissue biopsy truly is the gold standard for genetic analyses, but in some cases, such as with inadequate localization of the lesion or a patient’s inadequate performance status, comorbidities, or unwillingness to undergo an invasive procedure, liquid biopsy-based ctDNA analysis can be a noninvasive alternative approach. However, in some cases the gold standard might not shine that much. It is known that tumor heterogeneity or an inadequate amount of tissue might significantly interfere with the results of testing. In this paper, we present cases of patients with a negative tissue biopsy but a positive liquid biopsy which identified coexisting T790M mutation. These results enabled adequate sequencing and treatment with third-line EGFR-TKIs. Such possibilities stress the need to individualize testing for driver mutations in cases where it is clinically highly indicated.